目的:GlyH-101和CaCCinh-A01是囊性纤维化跨膜传导调节因子(CFTR)和Ca2激活的氯通道(CaCCs)的有效阻滞剂,分别。现有证据表明GlyH-101和CaCCinh-A01可以抑制细胞增殖,阻滞侵袭和转移,并导致几种癌细胞类型发生凋亡,证明了它们的抗肿瘤特性。这项研究的目的是研究GlyH-101和CaCCinh-A01对HT-29细胞活性的影响,并提出CFTR和CaCC抑制剂抑制HT-29细胞活性的可能分子机制。
方法:用GlyH-101或CaCCinh-A01或GlyH-101加CaCCinh-A01复合物处理人结肠HT-29癌细胞。MTT法测定细胞活力,流式细胞术检测细胞凋亡和细胞周期,和活性氧(ROS)水平由2',7'-二氯二氢荧光素二乙酸染色。通过蛋白质印迹法测量与凋亡和细胞周期调节相关的蛋白质的表达。
结果:GlyH-101和CaCCinh-A01对HT-29细胞的增殖能力呈剂量和时间依赖性降低。用GlyH-101和CaCCinh-A01处理导致细胞坏死和凋亡,ROS水平上调,激活线粒体凋亡途径,促使细胞周期停滞在S期,并增加与细胞周期相关的蛋白质水平。此外,与单独处理GlyH-101或CaCCinh-A01相比,这两种抑制剂的组合对HT-29细胞增殖具有更强的调节作用.
结论:GlyH-101和CaCCinh-A01在体外通过细胞周期阻滞和线粒体相关通路抑制细胞增殖。这些抑制剂的组合可以进一步增强它们的抗增殖作用。我们的发现提出了具有抗结肠癌活性的新先导化合物,同时也为氯通道靶向治疗在抗癌治疗中的有效性提供了新的证据。
OBJECTIVE: GlyH-101 and CaCCinh-A01 are effective blockers of cystic fibrosis transmembrane conductance regulator (CFTR) and Ca2+-activated chloride channels (CaCCs), respectively. Available evidence suggests that GlyH-101 and CaCCinh-A01 can suppress cell proliferation, block invasion and metastasis, and cause several cancer cell types to undergo apoptosis, demonstrating their anti-tumor properties. The aim of this study was to investigate the effect of GlyH-101 and CaCCinh-A01 on HT-29 cell activity and to suggest the possible molecular mechanisms by which inhibitors of CFTR and CaCCs inhibit HT-29 cell activity.
METHODS: Human colon HT-29 cancer cells were treated with GlyH-101 or CaCCinh-A01 or GlyH-101 plus CaCCinh-A01 complex. Cell viability was determined by MTT assay, the apoptosis and cell cycle were determined by flow cytometry, and reactive oxygen species (ROS) leves were determined by 2\',7\'-Dichlorodihydrofluorescein diacetate staining. The expression of proteins related to apoptosis and cell cycle regulation was measured by western blotting.
RESULTS: The proliferative ability of HT-29 cells was dose- and time-dependently reduced by GlyH-101 and CaCCinh-A01. Treatment with GlyH-101 and CaCCinh-A01 resulted in cell necrosis and apoptosis, up-regulated ROS levels, activated the mitochondrial apoptosis pathway, prompted arrest of the cell cycle in S phase, and increased the levels of proteins related to the cell cycle. Additionally, the combination of these two inhibitors had a stronger regulatory effect on HT-29 cell proliferation than either GlyH-101 or CaCCinh-A01 treated alone.
CONCLUSIONS: GlyH-101 and CaCCinh-A01 inhibited cell proliferation through cell cycle arrest and mitochondrial-related pathways in vitro. The combination of these inhibitors could further enhance their anti-proliferative effects. Our findings propose new lead compounds with anti-colon cancer activity, and also provide new evidence for the effectiveness of chloride channels-targeted therapy in anticancer therapy.